26. Cheung KL et al. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer: A study of its clinical and endocrine effects. Proc ASCO 2001; Abstract 1937.

27. Forward D et al. Combined use of goserelin (Zoladex)and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000; Abstract 582.

28. Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH)agonist versus LHRH agonist alone in premenopausal advanced breast cancer:A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. Abstract

29. Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging 2000;16:261-71. Abstract

30. Ellis MJ et al. A randomized double-blind multicenter study of preoperative tamoxifen versus Femara ® ((letrozole)for postmenopausal women with ER-and/or PgR positive breast cancer ineligible for breast-conserving surgery. Correlation of clinical response with tumor gene expression and proliferation. Breast Ca Res Treat 2000; Abstract 14.

31. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med
2001;344(11):783-92. Abstract

32. Vogel CL et al. Superior outcomes with Herceptin (trastuzumab) (H) in Fluorescence in situ hybridization (FISH)-selected patients. Proc ASCO 2001; Abstract 86.

33. Vogel C et al. First-line,single-agent Herceptin (trastuzumab)in metastatic breast cancer: A preliminary report. Eur J Cancer 2001;37 Suppl 1:S25-9. Abstract

OTHER CLINICAL TRIALS

NCI-G00-1906: Phase II Study of Exemestane and Goserelin in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. Protocol